Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Breier

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
Psychiatry Research. Neuroimaging|February 17, 2017
Association of medial prefrontal resting state functional connectivity and metacognitive capacity in early phase psychosisMichael M Francis, Tom A Hummer, Bethany L Leonhardt, et al.
The Journal of Clinical Endocrinology and Metabolism|December 13, 2003
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clampMargaret Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, et al.
JAMA Psychiatry|May 1, 2024
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical TrialInder Kaul, Sharon Sawchak, David P Walling, et al.
The American Journal of Psychiatry|October 4, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophreniaAlan Breier, Paul H Berg, Jogin H Thakore, et al.
Journal of Affective Disorders|January 1, 2003
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cyclingTodd M Sanger, Mauricio Tohen, Eduard Vieta, et al.
Schizophrenia Research|March 29, 2018
Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disordersAlan Breier, Emily Liffick, Tom A Hummer, et al.
Psychopharmacology|August 17, 2004
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjectsJohn H Krystal, Walid Abi-Saab, Edward Perry, et al.
Clinical EEG and Neuroscience|June 27, 2019
Relationship of Metacognition and Insight to Neural Synchronization and Cognitive Function in Early Phase PsychosisBethany L Leonhardt, Jenifer L Vohs, Lisa A Bartolomeo, et al.
International Journal of Geriatric Psychiatry|February 6, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's diseasePeter Paul De Deyn, Manuel Martín Carrasco, Walter Deberdt, et al.
Archives of General Psychiatry|May 2, 2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophreniaAlan Breier, Karena Meehan, Martin Birkett, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
Psychiatry Research. Neuroimaging|February 17, 2017
Association of medial prefrontal resting state functional connectivity and metacognitive capacity in early phase psychosisMichael M Francis, Tom A Hummer, Bethany L Leonhardt, et al.
The Journal of Clinical Endocrinology and Metabolism|December 13, 2003
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clampMargaret Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, et al.
JAMA Psychiatry|May 1, 2024
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical TrialInder Kaul, Sharon Sawchak, David P Walling, et al.
The American Journal of Psychiatry|October 4, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophreniaAlan Breier, Paul H Berg, Jogin H Thakore, et al.
Journal of Affective Disorders|January 1, 2003
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cyclingTodd M Sanger, Mauricio Tohen, Eduard Vieta, et al.
Schizophrenia Research|March 29, 2018
Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disordersAlan Breier, Emily Liffick, Tom A Hummer, et al.
Psychopharmacology|August 17, 2004
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjectsJohn H Krystal, Walid Abi-Saab, Edward Perry, et al.
Clinical EEG and Neuroscience|June 27, 2019
Relationship of Metacognition and Insight to Neural Synchronization and Cognitive Function in Early Phase PsychosisBethany L Leonhardt, Jenifer L Vohs, Lisa A Bartolomeo, et al.
International Journal of Geriatric Psychiatry|February 6, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's diseasePeter Paul De Deyn, Manuel Martín Carrasco, Walter Deberdt, et al.
Archives of General Psychiatry|May 2, 2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophreniaAlan Breier, Karena Meehan, Martin Birkett, et al.
Pageof 11